Blog

Synthomer plc (LSE:SYNT) reported a robust trading performance during the first half of 2026, with increases in volume, revenue, EBITDA and margins across its continuing operations.

The improvement was driven by stronger activity within the Coatings & Construction Solutions division and resilient performance from Adhesive Solutions. The company also cited healthy end-market demand, targeted growth investments and ongoing cost-saving initiatives as key contributors to the positive performance.

While Health & Protection and Performance Materials experienced a slower start to the year, management noted that volumes strengthened as the period progressed.

Second-Quarter Momentum Builds

Trading conditions improved further during the second quarter, with Synthomer successfully managing supply chain disruption linked to the conflict involving Iran.

The company utilised its global manufacturing network and procurement capabilities to maintain supply and mitigate operational challenges. Higher raw material and energy costs were largely passed through to customers, helping to protect profitability despite a more volatile cost environment.

Management highlighted the flexibility of the group’s regional production footprint as an important competitive advantage during periods of market disruption.

Balance Sheet Strengthened Through Refinancing

Synthomer also completed a refinancing of its bank debt facilities, improving liquidity and increasing covenant headroom.

The enhanced financial flexibility supports the company’s ongoing transformation programme, which remains focused on reducing leverage, streamlining operations and concentrating resources on higher-growth areas of the business.

As part of this strategy, Synthomer continues to progress the disposal of non-core assets, including the recently announced sale of its Acrylate Monomers business.

Management believes these actions will further strengthen the balance sheet while simplifying the group’s portfolio and improving strategic focus.

Outlook

Despite the strong operational performance reported in the first half, Synthomer’s longer-term outlook remains influenced by the impact of historical losses and uneven revenue trends experienced over recent years.

However, balance sheet leverage has improved, and the company benefited from stronger cash flow generation during 2025, providing additional support for its transformation plans.

Technical indicators remain a notable positive, with the shares trading above key moving averages and momentum measures such as MACD remaining supportive. Nevertheless, overbought signals suggest the potential for short-term share price volatility.

Valuation remains constrained by a negative price-to-earnings ratio, reflecting the company’s recent earnings profile. Management believes that continued operational improvements, portfolio simplification and debt reduction should support further progress over time.

More about Synthomer

Synthomer plc is a London-listed manufacturer of specialised polymers and performance ingredients serving customers across the coatings, construction, adhesives, healthcare and protection sectors.

The group operates through three divisions: Coatings & Construction Solutions, Adhesive Solutions, and Health & Protection and Performance Materials. Its products are supplied to more than 6,000 customers worldwide through a network of 29 manufacturing facilities.

By focusing on high-performance and specialised applications, Synthomer aims to provide innovative materials that support a broad range of industrial and consumer end markets while driving long-term value creation through operational excellence and portfolio optimisation.

CelLBxHealth plc (LSE:CLBX) reported a significant decline in revenue for 2025, with sales falling to £1.4 million as the company faced weaker demand for its biopharma services and incurred costs associated with a major restructuring programme.

The company recorded an operating loss of £19.2 million for the year, reflecting both the revenue reduction and restructuring-related charges. In response, management has undertaken extensive cost-cutting measures designed to improve efficiency and strengthen the business’s financial position.

Restructuring Delivers Significant Cost Savings

During the year, CelLBxHealth completed an £8.2 million fundraising and ended the reporting period with cash reserves of £7.3 million.

The company stated that its restructuring programme has reduced annualised operating cash costs to approximately £6.7 million. Key measures included a 60% reduction in headcount, consolidation of operational sites and renegotiation of supplier agreements.

Management believes these actions have created a leaner organisation capable of supporting future growth while reducing ongoing cash consumption.

Strategic Shift Towards Commercial Partnerships

Under the leadership of new chief executive Peter Collins and a refreshed board, CelLBxHealth has repositioned the business away from a predominantly research-focused model towards a more commercially driven strategy centred on partnerships and revenue generation.

The company has strengthened relationships with several major industry participants, including QIAGEN, Roche Diagnostics, Illumina and Myriad. It has also secured a new master service agreement with AstraZeneca, which management views as an important validation of the company’s technology and commercial capabilities.

These collaborations are expected to support a growing pipeline of opportunities and broaden the adoption of the company’s circulating tumour cell (CTC) platform.

Revenue Growth Targeted for 2026

Looking ahead, CelLBxHealth expects revenue of at least £2.1 million in 2026, representing growth from 2025 levels.

Management believes the combination of lower operating costs, strategic partnerships and increasing commercial activity will help stabilise the business while extending its cash runway into the second quarter of 2027.

The company is focused on converting its expanding pipeline into recurring revenue opportunities and strengthening its position within the oncology diagnostics and research markets.

Outlook

CelLBxHealth’s outlook remains influenced by significant financial challenges, including recent losses and the need to demonstrate sustainable revenue growth. Technical indicators also remain broadly negative, reflecting cautious market sentiment.

However, recent operational achievements, commercial partnerships and progress in reducing the company’s cost base provide encouraging signs as management works to reposition the business for long-term growth.

While valuation and financial risks remain important considerations, the company believes its strategic transformation and expanding industry relationships could create a stronger foundation for future performance.

More about CelLBxHealth

CelLBxHealth plc is a UK- and U.S.-based life sciences company specialising in circulating tumour cell (CTC) technologies for cancer research, drug development and clinical oncology applications.

Its proprietary Parsortix platform is designed to capture and isolate circulating tumour cells from blood samples, enabling downstream analysis through imaging, proteomics and genomic testing workflows. The technology supports a range of applications across product sales, laboratory services and laboratory-developed tests, helping researchers and clinicians gain deeper insights into cancer biology and treatment response.

Avacta Group plc (LSE:AVCT) has reported significant progress across its oncology portfolio during 2026, advancing multiple programmes based on its proprietary pre|CISION platform while extending its financial runway into 2027.

The company highlighted a series of clinical and preclinical achievements spanning its Gen One, Gen Two and Gen Three development programmes. Among the key milestones was the initiation of patient dosing in the Phase 1 FOCUS-01 trial evaluating AVA6103, the company’s Gen Two lead candidate.

Avacta also presented preclinical data demonstrating favourable performance relative to leading antibody-drug conjugates and reported encouraging efficacy signals alongside an improved safety profile for its Gen One candidate AVA6000 in salivary gland cancer patients.

Pipeline Development Continues Across Multiple Generations

The company has continued to broaden its oncology pipeline through the advancement of AVA6207, its dual-payload Gen Three programme, while further expanding its intellectual property portfolio.

Management expects to make important decisions during the second half of 2026 regarding payload selection and the nomination of future clinical candidates, supporting the next phase of development for the pre|CISION platform.

The ongoing progress reflects Avacta’s strategy of building a diversified pipeline of tumour-activated peptide drug conjugates designed to improve the delivery of potent cancer therapies while limiting systemic toxicity.

Balance Sheet Strengthened Through New Funding

Financially, Avacta has reinforced its position through the addition of £19 million in new capital during 2026.

The funding has extended the company’s expected cash runway into early 2027 while also reducing outstanding convertible bond liabilities. Management noted that these measures have improved financial flexibility as the company continues to invest in clinical development and business development initiatives.

The group has also refreshed its governance structure with the appointment of a new Non-Executive Chairman and remains engaged in partnering discussions covering its first-, second- and third-generation oncology assets.

Outlook

Avacta’s outlook continues to be shaped by the typical challenges faced by clinical-stage biotechnology companies. Ongoing losses, continued cash consumption and balance sheet pressures remain important considerations for investors.

However, technical indicators provide a more supportive picture, with the share price trading above longer-term moving averages and momentum measures such as MACD remaining positive.

Management believes recent clinical progress, improvements in cash management and continued advancement of the pre|CISION platform strengthen the company’s position. Nevertheless, future growth remains dependent on securing partnerships, advancing clinical programmes successfully and maintaining adequate funding through key development milestones.

More about Avacta Therapeutics

Avacta Therapeutics, part of Avacta Group plc, is a clinical-stage oncology company focused on developing targeted cancer treatments using its proprietary pre|CISION platform.

The technology is designed to activate therapies selectively within tumour tissue by targeting fibroblast activation protein (FAP), enabling potent chemotherapy agents to be delivered directly to cancer cells while reducing exposure to healthy tissue.

Through its portfolio of tumour-activated peptide drug conjugates, Avacta is seeking to establish a new generation of oncology treatments within the emerging XDC (peptide drug conjugate) field, with the goal of improving efficacy and safety compared with conventional chemotherapy approaches.

Anglo Asian Mining plc (LSE:AAZ) has appointed Worley Europe Limited to undertake feasibility studies for the development of its Xarxar and Garadag copper deposits in Azerbaijan, marking a significant step in the company’s strategy to expand its copper production capabilities.

The studies will evaluate the use of heap leach and solvent extraction-electrowinning (SX-EW) technologies to produce copper metal directly on site. If implemented, the project would represent the first production of refined copper metal by both Anglo Asian Mining and Azerbaijan, potentially creating additional value by reducing dependence on concentrate exports and third-party smelting facilities.

Focus on Higher-Value Copper Production

Management believes on-site copper metal production could strengthen project economics by capturing more value within the production chain. The feasibility work will assess the technical and commercial viability of the proposed processing route and help determine the optimal development strategy for the two deposits.

The appointment of Worley, a global engineering and project delivery specialist, reflects the company’s intention to accelerate the advancement of its copper portfolio as demand for the metal continues to grow across energy transition and industrial markets.

Major Drilling Campaign Underway

Alongside the feasibility programme, Anglo Asian is launching an extensive 90,000-metre core drilling campaign across 2026 and 2027.

The programme will be divided between exploration drilling and work designed to support feasibility studies and future mine development. Activities will cover several key assets, including Xarxar, Garadag, Gedabek, Demirli and Gilar.

Management expects the drilling programme to contribute to resource expansion, reserve conversion and mine planning activities, while also supporting the development of new mining operations across its portfolio.

Long-Term Growth Strategy

The company views the combined feasibility and drilling initiatives as central components of its broader strategy to evolve into a mid-tier, multi-asset copper and gold producer.

By expanding its resource base and progressing multiple development projects simultaneously, Anglo Asian aims to build a larger and more diversified production platform capable of delivering sustainable long-term growth.

Management believes these investments will strengthen the company’s position within Azerbaijan’s mining sector and support future value creation for shareholders.

Outlook

Anglo Asian’s outlook is supported by an improvement in financial performance during 2025, including stronger profitability and a recovery in cash generation. However, earnings volatility, higher leverage and uneven cash conversion continue to present challenges.

Technical indicators remain positive, reflecting a strong upward trend in the shares, although overbought conditions suggest the potential for short-term consolidation or pullbacks.

Valuation remains a consideration for investors, with the shares trading on an elevated earnings multiple and no dividend yield currently highlighted. Nevertheless, management believes the company’s expanding copper pipeline provides a strong foundation for future growth.

More about Anglo Asian Mining

Anglo Asian Mining plc is an AIM-listed producer of gold, copper and silver with operations and exploration assets located across Azerbaijan.

Its portfolio includes producing and development-stage projects such as Gilar, Demirli and Gedabek. During 2025, the company produced 7,915 tonnes of copper and 25,061 ounces of gold and is pursuing a long-term objective of becoming a mid-tier, multi-asset copper and gold producer by 2030.

As part of this strategy, Anglo Asian is targeting annual copper production of between 50,000 and 55,000 tonnes through a combination of resource growth, new mine development and enhanced processing capabilities.

eEnergy Group plc (LSE:EAAS) has issued a trading update ahead of its annual general meeting, outlining revised expectations for FY26 following the appointment of interim chief executive John Gahan and a comprehensive review of the company’s sales pipeline.

Following the assessment, the board now believes that investment-grade opportunities valued at £66 million provide a more realistic indication of the revenue potential available from active projects over the near and medium term.

Cost-Cutting Measures Underway

The company has launched a restructuring programme designed to simplify operations and reduce costs, with annual operating expenses expected to fall by almost one-third.

Management expects the initiative to generate approximately £2 million in annualised savings during FY26. Despite a one-off restructuring charge, the programme is also forecast to improve second-half adjusted EBITDA by around £1 million, reflecting the anticipated benefits of a leaner operating structure.

The measures form part of a broader effort to strengthen profitability and improve operational efficiency as the company adapts to current market conditions.

Revenue and Earnings Guidance Revised

For the first half of 2026, eEnergy expects to report revenue of approximately £22 million and adjusted EBITDA of £1.2 million.

However, the company has reduced its full-year guidance and now anticipates FY26 revenue of around £32 million and adjusted EBITDA of £1.7 million. While these figures still represent growth compared with FY25, they are below previous expectations and indicate a lower profitability profile than originally forecast.

Management said the revised outlook reflects a more conservative assessment of project conversion timelines and near-term revenue opportunities.

Outlook

eEnergy’s outlook reflects a business in transition. Improvements in operational performance and the return to positive operating and free cash flow provide encouraging signs, particularly as the restructuring programme takes effect.

However, these positives are offset by a significant decline in revenue relative to prior expectations and increased balance-sheet risk resulting from a reduced equity base and higher leverage levels.

Technical indicators currently suggest a neutral-to-cautious market view, while valuation measures remain difficult to assess given the company’s negative earnings position. Management believes the restructuring programme and a more focused commercial strategy should provide a platform for improved performance over the longer term.

More about eEnergy Group

eEnergy Group plc is a UK-based Energy-as-a-Service provider that develops, finances and delivers energy efficiency and energy generation solutions for public sector and commercial organisations operating across multiple sites.

Its services include LED lighting and smart controls, solar photovoltaic systems, battery storage and electric vehicle charging infrastructure. The company typically funds projects through third-party financing arrangements and public procurement frameworks, with a particular focus on schools, colleges and other educational institutions seeking to reduce energy costs and carbon emissions.

Empire Metals Limited (LSE:EEE) has announced its strongest drilling results to date from the Thomas Prospect within the Pitfield titanium project in Western Australia, confirming the presence of a substantial high-grade titanium-rich core averaging 47 metres in thickness across an area of approximately 6.25 square kilometres.

The latest drilling programme included 178 air core and reverse circulation holes and delivered multiple mineralised intervals grading close to or above 8% TiO₂. Among the standout results was a two-metre section grading 21.44% TiO₂, further strengthening confidence in the scale and quality of the deposit while extending known mineralisation beyond the current resource boundaries.

Resource Upgrade Targeted for Third Quarter

The drilling campaign generated more than 5,000 laboratory samples, providing a significant volume of new data that will support an updated mineral resource estimate planned for the third quarter of 2026.

Management expects the revised resource to play a central role in future mine planning and engineering studies as the project advances towards development. The latest results are viewed as an important step in defining the overall scale of the Pitfield project and improving geological understanding of the mineralised system.

Development Activities Continue Across Pitfield

Grid drilling programmes have now been completed at both the Thomas and Cosgrove prospects, while additional exploration drilling has been undertaken across the broader project area to support resource definition and identify suitable locations for future infrastructure.

Empire Metals is progressing a range of technical workstreams designed to advance Pitfield towards development. These include engineering studies, ongoing pilot plant test work and product development programmes focused on coated rutile pigments and titanium sponge feedstock, both of which are expected to continue through late 2026.

Management believes the project has the potential to become a significant long-term source of titanium supply, serving industries that require titanium dioxide for pigments and titanium metal production.

Outlook

Empire Metals’ outlook remains influenced by its status as a development-stage company. The absence of revenue, continuing losses and ongoing cash expenditure mean the business remains reliant on future funding to support project advancement.

Market indicators also point to a challenging near-term picture, with the share price trading below major moving averages and momentum measures reflecting a broader downtrend. However, the company maintains a relatively low level of debt, providing some balance sheet stability as it continues to advance the Pitfield project.

Management believes that continued resource growth, technical progress and future development milestones could help unlock value as the project moves closer to commercialisation.

More about Empire Metals

Empire Metals Limited is an exploration and development company listed on AIM in London and quoted on the OTCQX market in the United States. The company focuses on the discovery and advancement of mineral resource projects, with a particular emphasis on titanium-bearing deposits.

Its flagship asset, the Pitfield Project in Western Australia, hosts extensive titanium dioxide mineralisation and is being developed with the objective of supplying raw materials for pigment production and titanium metal feedstock markets. Through ongoing exploration, resource expansion and technical development programmes, Empire aims to establish Pitfield as a significant future titanium resource.

Clean Power Hydrogen plc (LSE:CPH2) has announced a major strategic shift towards a licensing-led business model after an incident at its testing facility damaged an MFE220 1MW electrolyser during final factory acceptance testing.

The company confirmed that no injuries occurred and that its core membrane-free stack technology was not responsible for the incident. An extensive root cause investigation is underway, with a detailed technical report expected by the end of August 2026. Any required design modifications identified during the review will be incorporated into future testing programmes to ensure compliance with safety and performance standards.

Manufacturing Activities to End

Following a review of its available financial and engineering resources, Clean Power Hydrogen has decided to discontinue manufacturing operations and focus instead on research, technology development and the global licensing of its intellectual property.

Management concluded that completing full-scale manufacturing and any subsequent retesting programmes would require resources beyond those currently available to the business. The new strategy is intended to create a more capital-efficient operating model centred on commercialising the company’s proprietary technology through partnerships and licensing agreements.

The group currently holds 16 patents across 12 jurisdictions and has secured licensing agreements in twelve countries. It is also exploring additional strategic alliances and manufacturing partnerships while continuing discussions with insurers regarding the testing incident. Separately, the company is reviewing the status of its sales agreement with Lagan MEICA.

Leadership Changes to Support Strategic Transition

As part of the transformation, Richard Scott is expected to become chief executive, subject to the completion of regulatory checks. James Hobson will continue as chief financial officer, while Natalie Fortescue has been appointed non-executive chair.

The current chief executive and chair are expected to step down following the company’s next fundraising. The board said the leadership changes are designed to support the transition towards a technology licensing business focused on monetising intellectual property rather than manufacturing equipment internally.

Fundraising and Cost Reduction Plans

Clean Power Hydrogen is implementing a significant cost-reduction programme as it restructures the business around its new strategy. The company is also engaged in discussions with potential investors and advisers regarding a proposed fundraising that may include a subscription, placing and retail offer.

Management intends to use the proceeds to strengthen working capital, support the licensing-focused business model and facilitate the restoration of trading in the company’s AIM-listed shares.

The company cautioned that securing additional capital remains critical. Current cash resources are expected to support operations only until mid-July 2026, and failure to complete a fundraising or secure alternative financing would place severe pressure on working capital.

Outlook

Clean Power Hydrogen’s outlook remains heavily influenced by a weak financial position, characterised by minimal revenue generation, widening losses, substantial cash burn and a significantly reduced equity base.

From a market perspective, technical indicators are more supportive, with the shares showing positive momentum and an upward trend. However, elevated RSI readings suggest the potential for increased volatility or a short-term pullback.

Valuation metrics remain difficult to assess given the company’s ongoing losses and the absence of a dividend policy. Management believes that successfully executing the transition to a licensing-based model could provide a more sustainable route to commercialising its technology over the longer term.

More about Clean Power Hydrogen

Clean Power Hydrogen plc is a UK-based clean energy technology company specialising in membrane-free electrolysers used for hydrogen production.

The company develops proprietary electrolyser stack technology designed to support the production of green hydrogen and has built an international intellectual property portfolio covering multiple jurisdictions. Through licensing agreements and strategic partnerships, Clean Power Hydrogen aims to expand the adoption of its technology while reducing the capital requirements associated with large-scale manufacturing operations.

BATM Advanced Communications Ltd (LSE:BVC) has agreed a series of transactions expected to generate approximately $37 million, supporting its strategy to streamline operations and concentrate on its core networking and cybersecurity businesses.

The company has entered into agreements to sell three of its four remaining non-core business activities, comprising seven separate entities, for a total consideration of $13.3 million. In addition, BATM will dispose of 96.8 million treasury shares currently held by Sunstring for approximately $23.3 million, representing a 33% premium to the recent market price.

Following completion of the transactions, investor Haim Dor is expected to hold approximately 22% of the company.

Capital to Support Growth and Strategic Expansion

Management intends to use the proceeds to accelerate investment in research and development, expand commercial operations and pursue strategic acquisition opportunities.

The transactions represent a significant step in BATM’s ongoing transformation programme, which aims to exit non-core activities and establish the group as a more focused provider of high-growth networking and cybersecurity solutions.

The company believes the additional financial resources will strengthen its ability to invest in key technologies and capture opportunities across its target markets.

Simplified Structure and Potential Additional Upside

The disposal agreements include staged payment arrangements, as well as customary warranty and non-compete provisions. They also feature an earn-out mechanism that could provide BATM with additional proceeds if the acquired businesses are sold on at a valuation above an agreed threshold within the next two years.

Subject to shareholder approval and the completion of a planned corporate reorganisation, the transaction will leave only one remaining non-core environmental monitoring subsidiary to be divested. Management believes this will further simplify the group’s structure and improve operational focus.

The streamlined business model could also enhance balance sheet strength and provide greater flexibility for future strategic initiatives.

Outlook

BATM’s investment case continues to be affected by weak financial performance, with ongoing losses and recent cash outflows offsetting the benefits of revenue growth and a relatively low level of debt.

Technical indicators offer only limited support at present, while valuation remains constrained by negative earnings. However, management believes that the disposal programme and renewed focus on higher-growth markets should create a stronger platform for long-term value creation.

More about BATM Advanced Communications

BATM Advanced Communications is a global technology company listed in both London and Tel Aviv, specialising in advanced networking infrastructure and cybersecurity solutions.

The group provides secure managed networking, quantum encryption and cyber defence technologies to government agencies, critical infrastructure operators and enterprise customers. Through its focus on secure communications and next-generation networking, BATM aims to address the growing demand for resilient digital infrastructure and advanced cyber protection.